Healthcare / Drug Manufacturers - Specialty & GenericBSE
$261.50
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-31.6M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.9B
P/E
27.9x
↑EV/EBITDA
27.4x
↑ROE
14.3%
↑Gross Margin
28.3%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+126.2%
FCF CAGR
—
FCF margin
-71.4%
FCF / Net income
-4.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $336.0M · net income $50.7M · FCF $-240.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $336.0M | $336.0M | $160.0M | $50.1M | $29.0M |
| Net Income | $50.7M | $50.7M | $25.0M | $8.2M | $2.8M |
| EBITDA | $70.1M | $70.1M | $37.3M | $14.0M | $7.6M |
| EPS | — | — | 3.45 | 1.14 | 0.39 |
| Gross Margin | 28.3% | 28.3% | 34.0% | 35.0% | 34.5% |
| Operating Margin | 19.7% | 19.7% | 21.9% | 23.0% | 16.4% |
| Net Margin | 15.1% | 15.1% | 15.6% | 16.4% | 9.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.72 | 2.00 | 7.50 |
| Current Ratio | 14.27 | 14.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-240.1M | $-240.1M | $-31.6M | $719000.00 | $6.8M |
| Returns | |||||
| ROE | 14.3% | 14.3% | 46.8% | 75.8% | 106.7% |
| Valuation | |||||
| P/E | 27.94 | 27.94 | — | — | — |
| EV/EBITDA | 27.45 | 27.45 | — | — | — |
| P/B | 5.34 | 5.34 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 110.0% | 110.0% | 219.7% | 72.4% | — |
| EPS Growth | — | — | 204.3% | 192.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+36.8%
Start / end P/E
n/dx → n/dx
EPS bridge
3.45 → n/d
Residual
+36.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.